Patents Examined by Celia Chang
  • Patent number: 9546164
    Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: January 17, 2017
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Paul Robert Bichler, Chien-An Chen, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Zhiguo Liu, Daniel F. Ortwine, Brian Safina, Daniel Sutherlin, Tao Sheng, Shaoyi Sun, Andrew D. White, Michael Scott Wilson, Alla Yurevna Zenova, Jiuxiang Zhu
  • Patent number: 9545105
    Abstract: The present invention relates to fungicidal 1-(heterocyclic carbonyl) piperidines and their thiocarbonyl derivatives, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: January 17, 2017
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Jurgen Benting, Peter Dahmen, Philippe Desbordes, Stephanie Gary, Jean-Pierre Vors, Ulrike Wachendorff-Neumann
  • Patent number: 9546139
    Abstract: Provided are a novel pyridine carboxylic acid based compound used as a P2X1 and P2X3 receptor antagonist, a production method for the same and a composition comprising the same. The compound according to the present invention is a powerful antagonist of P2X1 and P2X3 receptors, and hence can be used as a drug for treating or preventing diseases involving neurological pain or chronic inflammatory diseases which are diseases caused by P2X1 and P2X3 receptor activity.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: January 17, 2017
    Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Yong-Chul Kim, Kwan-Young Jung, Joong Heui Cho
  • Patent number: 9539248
    Abstract: This invention provides a safe and effective agent for ameliorating chronic obstructive pulmonary disease (COPD) that has both a bronchodilator effect and an anti-inflammatory effect. The agent for ameliorating chronic obstructive pulmonary disease contains mepenzolate bromide as an active ingredient. More preferably the mode of administration of the agent for ameliorating chronic obstructive pulmonary disease is airway administration or inhalation administration, and furthermore the mode of administration thereof is oral administration or rectal administration. This invention is a safe and effective agent for ameliorating chronic obstructive pulmonary disease (COPD) that has both a bronchodilator effect and an anti-inflammatory effect of mepenzolate bromide.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: January 10, 2017
    Assignee: LTT Bio-Pharma Co., Ltd.
    Inventors: Toru Mizushima, Hongxing Liu
  • Patent number: 9533973
    Abstract: The disclosure is directed to compounds identified as allosteric modulators of 5-HT 2CR, as well as pharmaceutical compositions and methods using the same. Certain embodiments also include methods of identifying and methods of synthesizing the compounds. Optimization and development of allosteric 5-HT 2CR modulators that bind sites other than the primary ligand binding site generate novel, highly selective, and potent ligands of 5-HT2CR. Such molecules can be used as small molecule probes for the nervous system and as effective therapeutics for a variety of diseases.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: January 3, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jia Zhou, Chunyong Ding, Kathryn A. Cunningham
  • Patent number: 9533951
    Abstract: Disclosed are a variety of amphoteric compounds having a heterocyclic quaternary nitrogen group. The heterocycle includes pyridines, piperidines, and pyrrolidines, and is linked to the hydrophobe via either an amide or an ester linkage. These heterocyclic amphoteric compounds can be advantageously prepared in high yield and purity by a two-step chemoenzymatic process, and have excellent surfactant properties.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: January 3, 2017
    Assignee: Eastman Chemical Company
    Inventors: Neil Warren Boaz, Matthew Allen Boone
  • Patent number: 9527830
    Abstract: This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: December 27, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Shawn Walsh, Alexander Pasternak, Brian Cato, Paul E. Finke, Jessica Frie, Qinghong Fu, Dooseop Kim, Barbara Pio, Aurash Shahripour, Zhi-Cai Shi, Haifeng Tang
  • Patent number: 9527835
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: December 27, 2016
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Ding-Quan Qian, Bo Shen, Wenqing Yao
  • Patent number: 9527850
    Abstract: The invention provides novel substituted benzyl piperidine compounds according to Formula (I) as lysophosphatidic acid (LPA) receptor antagonists, their manufacture and use for the treatment of proliferative or inflammatory diseases, such as cancer, fibrosis or arthritis.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: December 27, 2016
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, Wolfgang Staehle, Michael Busch, Dirk Wienke, Oliver Poeschke, Christa Burger
  • Patent number: 9522899
    Abstract: The present invention discloses methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2,6-dioxopiperidine and intermediates thereof, namely, the synthesis of compounds of the Formula (I), with each substitutional group defined in the patent specification. Owing to the advantages of high productivity, little influence to the environment and material accessibility, the methods of the present invention is suitable for industrial production.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: December 20, 2016
    Assignees: NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD
    Inventors: Rong Yan, Hao Yang, Yongxiang Xu
  • Patent number: 9522903
    Abstract: Multifunctional nitroxide derivatives comprising a potassium channel opener and a reactive oxygen species (ROS) degradation catalyst that can act as an anti-oxidant, as well as pharmaceutical compositions comprising them are provided. The multifunctional compounds and pharmaceutical compositions are useful for treatment of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: December 20, 2016
    Assignee: Radikal Therapeutics Inc.
    Inventors: Prakash Jagtap, Andrew Lurie Salzman
  • Patent number: 9522883
    Abstract: The invention provides compounds of Formula (I) for inhibiting gh cosidases, prodrugs of the compounds, and pharmaceutical compositions comprising the compounds or prodrugs of the compounds. The invention also provides method of treating diseases and disorders related to deficiency or over-expression of O-gh coprotein 2-acetamido-2-deoxy-?-D-glucopyranosidase (O-GlcNAcase), accumulation or deficiency of 2-acetamido-2-deoxy-?-D-glucopyranoside (O-GlcNAc).
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: December 20, 2016
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Harold G. Selnick
  • Patent number: 9518054
    Abstract: Compounds of formula (I) wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O—, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C—R5 or N; B is C—R6 or N; D is C—R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R10 is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: December 13, 2016
    Assignee: GLAXO GROUP LIMITED
    Inventors: Stephen John Atkinson, Michael David Barker, Matthew Campbell, Hawa Diallo, Clement Douault, Neil Stuart Garton, John Liddle, Robert John Sheppard, Ann Louise Walker, Christopher Wellaway, David Matthew Wilson
  • Patent number: 9512117
    Abstract: Heteroarylpiperidine and -piperazine derivatives of the formula (I) in which the symbols A, X, Y, L1, L2, G, Q, p, R1, R2 and R10 are each as defined in the description, and salts, metal complexes and N-oxides of the compounds of the formula (I), and the use thereof for controlling phytopathogenic harmful fungi and processes for preparing compounds of the formula (I).
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: December 6, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Stefan Hillebrand, Pierre Cristau, Sebastian Hoffmann, Joachim Kluth, Pierre Wasnaire, Tomoki Tsuchiya, Juergen Benting, Ulrike Wachendorff-Neumann, Thomas Seitz
  • Patent number: 9512106
    Abstract: Compounds of general Formulas (I), (IA), (IB) are described, along with compositions containing the same and methods of use thereof, inhibiting the hedgehog pathway in a cell or inhibiting unwanted proliferation of a cell.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: December 6, 2016
    Assignee: Duke University
    Inventors: Wei Chen, Jiangbo Wang, Robert A. Mook, Jr., Lawrence S. Barak, H. Kim Lyerly, Anthony Angelo Ribeiro
  • Patent number: 9512077
    Abstract: The present invention relates to an industrially feasible and economically viable process for the preparation of methylphenidate hydrochloride of formula I and its intermediates thereof.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: December 6, 2016
    Assignee: ZCL CHEMICALS LTD.
    Inventors: Agarwal Nand Lal, Chandrashekhar Singh, Mubashshir Ahmed, Bhavsar Rahul Arunbhai
  • Patent number: 9505717
    Abstract: An acetic acid ester compound represented by the following formula (I) or a salt thereof, wherein R represents optionally substituted deuterated lower alkyl, is disclosed.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: November 29, 2016
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Masato Nanri, Yoshikazu Iwasawa, Fukumitsu Sakakibara, Shinichi Aoki
  • Patent number: 9493438
    Abstract: The invention, in a first aspect relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is a 6-membered aromatic ring, or a 5- or 6-membered heteroaromatic ring comprising 1 to 3 heteroatoms selected from S, O and N, or a 6-membered benzocondensed heteroaromatic ring containing N as heteroatom, optionally each of said rings being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl, cyano, trifluoromethyl, dimethylamino, or phenyl which optionally is substituted with one or more halogen atoms, or a 5- or 6-membered heterocycle containing from one to three nitrogen atoms; X is O or N; P is pyridyl, pyrimidyl, pyrazyl, or pyridazyl, each being optionally substituted with one or more substituents selected from the group consisting of (C1-C3)alkyl, halogen, trifluoromethyl, and cyano, and use thereof as pharmaceuticals.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: November 15, 2016
    Assignee: Rottapharm S.R.L.
    Inventors: Luigi Piero Stasi, Lucio Rovati, Roberto Artusi, Clara Bovino, Fabrizio Colace, Stefano Mandelli
  • Patent number: 9487512
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: November 8, 2016
    Assignee: Oryzon Genomics S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Angeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Patent number: 9475770
    Abstract: The present invention describes a process for the preparation of methylphenidate hydrochloride. The process involves the esterification of ritalinic acid and methanol in the presence of an acid catalyst at a low temperature. The process may optionally involve the addition of an orthoester.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: October 25, 2016
    Assignee: Rhodes Technologies
    Inventors: C. Frederick M. Huntley, Erik Wayne Kataisto, Knicholaus Dudley La Lumiere, Helge Alfred Reisch